Company Report
`
`MSD OSS BV
`
`Molenstraat 110
`Oss, 5342 CC
`Netherlands
`www.msd.nl
`31-41-266-1222
`Generated 05/23/2023
`
`12
`
`Table of Contents
`Company Overview.....................................................
`Company Hierarchy....................................................
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 1
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`Company Overview
`DESCRIPTION
`MSD Oss B.V. operates as a pharmaceutical company. The Company develops, produces, and packages pharmaceutical products including tablets and
`injections, and dosage forms. MSD operates worldwide.
`QUICK-PROFILE
`Country Of Incorporation
`State Of Incorporation
`Fiscal Year End
`Website
`Employees
`Transfer Agent
`Auditor
`Primary Exchange
`Sector
`Industry Group
`Industry Sub-Group
`SIC Code
`SIC Name
`Equity Float
`Institutional Ownership
`Phone
`Last Closing Price
`Market Capitalization
`52 Week High
`52 Week Low
`Shares Outstanding
`Last Dividend
`Cash Flow From Operations
`Cash And Near Cash Items
`
`Netherlands
`N.A.
`N.A.
`www.msd.nl
`N.A.
`N.A.
`N.A.
`N.A.
`Consumer, Non-cyclical
`Pharmaceuticals
`Medical-Drugs
`N.A.
`N.A.
`N.A.
`N.A.
`31-41-266-1222
`N.A.
`N.A.
`N.A.
`N.A.
`N.A.
`N.A.
`N.A.
`N.A.
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`1
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 2
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`Company Hierarchy
`Merck & Co Inc
`|----7728026 Canada Inc(Subsidiary, Canada(QC))
`|----Aacifar-Produtos Quimicos e Farmaceuticos Sociedade Uni Lda(Related Entity, Portugal)
`|----Abmaxis Inc(Subsidiary, United States(DE))
`|----Acceleron Pharma Germany GmbH(Related Entity, Germany)
`|----Acceleron Pharma Inc(Subsidiary, United States(DE))
`|--------Acceleron Holding Ltd(Subsidiary, Bermuda)
`|--------Acceleron Pharma Switzerland AG(Subsidiary, Switzerland)
`|--------Acceleron Securities Corp(Subsidiary, United States(MA))
`|----Acceleron Pharma Netherlands BV(Related Entity, Netherlands)
`|----Administradora Schering Plough S de RL de CV(Related Entity, Mexico)
`|----AESCA Pharma GmbH(Related Entity, Austria)
`|----Afferent Pharmaceuticals Inc(Subsidiary, United States(DE))
`|----Agrident GmbH(Subsidiary, Germany)
`|----Agro Verhen BV(Subsidiary, Netherlands)
`|----Aleis Pty Ltd(Subsidiary, Australia(QL))
`|----Allflex Argentina SA(Subsidiary, Argentina)
`|----Allflex Australia Pty Ltd(Subsidiary, Australia)
`|----Allflex Avrasya Havyan Kimlik Sistemleri San Ve Ticaret Ltd Sti(Related Entity, Turkey)
`|----Allflex China Intelligent Technology Co Ltd(Related Entity, China)
`|----Allflex Dan-mark ApS(Subsidiary, Denmark)
`|----Allflex Europe Holdings 1 BV(Subsidiary, Netherlands)
`|----Allflex Europe Holdings 2 BV(Subsidiary, Netherlands)
`|----Allflex Europe Holdings 3BV(Subsidiary, Netherlands)
`|----Allflex Europe SASU(Subsidiary, France)
`|----Allflex Group Germany GmbH(Subsidiary, Germany)
`|----Allflex Holdings 1 Inc(Subsidiary, United States(DE))
`|----Allflex Holdings 2 Inc(Subsidiary, United States(DE))
`|----Allflex Holdings 3 Inc(Subsidiary, United States(DE))
`|----Allflex India Pvt Ltd(Subsidiary, India)
`|----Allflex International DO Brasil Ltda(Subsidiary, Brazil)
`|----Allflex Maroc Sarl(Subsidiary, Morocco)
`|----Allflex New Zealand Ltd(Subsidiary, New Zealand)
`|----Allflex Polska Sp zoo(Subsidiary, Poland)
`|----Allflex Scr Vostok(Subsidiary, Belarus)
`|----Allflex Services SARLU(Subsidiary, France)
`|----Allflex UK Group Ltd(Subsidiary, Britain)
`|----Allflex USA Inc/DE(Subsidiary, United States(DE))
`|----Alta Plastic Muhendislik Sanayi VE Ticaret Ltd Sirketi(Related Entity, Turkey)
`|----American Image Productions Inc(Related Entity, United States(TN))
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`2
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 3
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Amrad Pharmaceuticals Pty Ltd(Related Entity, Australia)
`|----Animal Health Registration World Wide Pty Ltd(Related Entity, South Africa)
`|----Animal ID Australia Pty Ltd(Related Entity, Australia(QL))
`|----Antelliq Corp(Related Entity, United States(DE))
`|----Antelliq Finance Inc(Subsidiary, United States(DE))
`|----Antelliq Holdings France SASU(Subsidiary, France)
`|----Antelliq Holdings Inc(Related Entity, United States(DE))
`|----Antelliq Management Inc(Related Entity, United States(DE))
`|----Antimicrobial Stewardship LLC(Subsidiary, United States(DE))
`|--------Teqqa LLC(Subsidiary, United States(WY))
`|----Aptus Health Holdings Inc(Related Entity, United States(DE))
`|----Aptus Health Inc(Related Entity, United States(DE))
`|--------Engaged Media LLC(Subsidiary, United States)
`|--------InfoMedics Inc(Related Entity, United States)
`|--------MedManage Systems Inc(Subsidiary, United States)
`|--------Quantia Inc(Subsidiary, United States)
`|--------Tomorrow Networks LLC(Related Entity, United States)
`|----Aptus Health International France SAS(Related Entity, France)
`|----Aptus Health International Inc(Related Entity, United States(DE))
`|----Aptus Health International UK Pvt Ltd(Related Entity, Britain)
`|----Aquaculture Vaccines Ltd(Related Entity, Britain)
`|----ArQule Inc(Subsidiary, United States(DE))
`|--------Arqule Biotech Drug Discovery(Subsidiary, United States)
`|----Aspen API Inc(Related Entity, United States(DE))
`|----Bain de Soleil Co Inc/The(Related Entity, United States(DE))
`|----Banyu Pharmaceutical Co Ltd(Related Entity, Japan)
`|----Beijing Allflex Plastic Products Co Ltd(Subsidiary, China)
`|----Beijing Protection Science & Technology Co Ltd(Subsidiary, China)
`|----Beneficiadora e Industrializadora SA de CV(Related Entity, Mexico)
`|----BioConnection(Related Entity, Netherlands)
`|----Biomark Inc(Subsidiary, United States(ID))
`|----Biometer International A/S(Related Entity, Denmark)
`|----Biotest KK(Subsidiary, Japan)
`|----Blue Jay Investments CV(Subsidiary, Netherlands)
`|----BRC Ltd/Bermuda(Subsidiary, Bermuda)
`|--------Capital Structures PLC(Subsidiary, Britain)
`|----BSSN Software GmbH(Subsidiary, Germany)
`|----Burgwedel Biotech GmbH(Subsidiary, Germany)
`|----Calporta Therapeutics Inc(Subsidiary, United States(DE))
`|----Cambridge Resonant Technologies Ltd(Subsidiary, Britain)
`|----Canji Inc(Subsidiary, United States(DE))
`|----cCAM Biotherapeutics Ltd(Subsidiary, Israel)
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`3
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 4
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Chemibiotic Ireland Ltd(Related Entity, Ireland)
`|----Cherokee Pharmaceuticals LLC(Subsidiary, United States(DE))
`|----Cherokee Riverside Holdings Inc(Related Entity, United States(DE))
`|----Chevillot SAS(Subsidiary, France)
`|----Chibret A/S(Subsidiary, Denmark)
`|----Chibret Pharmazeutische GmbH(Related Entity, Germany)
`|----China-MSD HIV AIDS PPP Inc(Subsidiary, China(DE))
`|----Chippewa Holdings LLC(Subsidiary, United States(DE))
`|----Cloverleaf International Holdings Sarl(Related Entity, United States)
`|----CM Delaware LLC(Subsidiary, United States(DE))
`|----CO Veterinary Holdings Inc(Subsidiary, Panama)
`|----Comsort Inc(Related Entity, United States(DE))
`|----Controladora Msd Mexicana Srl de Capital Variable(Subsidiary, Mexico)
`|----Cooper Veterinary Products Pty Ltd(Subsidiary, South Africa)
`|----Coopers Saude Animal Industria e Comercio Ltda(Related Entity, Brazil)
`|----Coopers Uruguay SA(Related Entity, Uruguay)
`|----Coopers Veterinary Products Pty Ltd(Related Entity, South Africa)
`|----Corp Allflex Inc(Subsidiary, Canada)
`|----Cosmas BV(Subsidiary, Netherlands)
`|----Crosswinds BV(Related Entity, Netherlands)
`|----Cubist Bermuda Ltd(Related Entity, Bermuda)
`|----Cubist Pharmaceuticals Espana SLU(Related Entity, Spain)
`|----Cubist Pharmaceuticals LLC(Subsidiary, United States(DE))
`|--------Adolor Corp(Subsidiary, United States(DE))
`|--------Calixa Therapeutics Inc(Subsidiary, United States(DE))
`|--------Cubist Pharmaceuticals Canada Inc(Subsidiary, Canada)
`|--------Cubist Pharmaceuticals Danmark ApS(Related Entity, Denmark)
`|--------Cubist Pharmaceuticals Deutschland GmbH(Subsidiary, Germany)
`|--------Cubist Pharmaceuticals France SAS(Related Entity, France)
`|--------Cubist Pharmaceuticals GmbH(Related Entity, Switzerland)
`|--------Cubist Pharmaceuticals Holdings LLC(Related Entity, United States(DE))
`|--------Cubist Pharmaceuticals Italia Srl(Related Entity, Italy)
`|--------Cubist Pharmaceuticals US(Related Entity, United States(KY))
`|--------Illumigen Biosciences Inc(Subsidiary, United States(WA))
`|--------Optimer Bermuda LP(Subsidiary, Bermuda)
`|--------Optimer Luxembourg 1SARL(Subsidiary, Luxembourg)
`|--------Optimer Luxembourg 2SARL(Subsidiary, Luxembourg)
`|--------Optimer Pharmaceuticals LLC(Related Entity, United States(DE))
`|------------Optimer Pharmaceuticals Canada Inc(Subsidiary, Canada)
`|--------Optimer Pharmaceuticals US Holdings LLC(Subsidiary, United States(DE))
`|--------Trius Therapeutics LLC(Related Entity, United States(DE))
`|----Desarrollos Farmaceuticos y Cosmeticos SA(Related Entity, Spain)
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`4
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 5
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Dialstat Trading 91 Pty Ltd(Subsidiary, South Africa)
`|----Dieckmann Arzneimittel GmbH(Related Entity, Germany)
`|----Digital Angel SA(Subsidiary, Argentina)
`|----Diosynth Apeldoorn BV(Related Entity, Netherlands)
`|----Diosynth France SASU(Subsidiary, France)
`|----Diosynth Holding BV(Subsidiary, Netherlands)
`|----Diosynth International BV(Related Entity, Netherlands)
`|----Diosynth Produtos Farmo-quimicos Ltda(Subsidiary, Brazil)
`|----Distrireti SA(Related Entity, France)
`|----DJT Partners LP(Related Entity, United States(DE))
`|----DNAX Research Inc(Related Entity, United States(CA))
`|----DNAX Research Institute of Molecular and Cellular Biology Inc(Related Entity, United States(CA))
`|----Douglas Industries Inc(Related Entity, United States(DE))
`|----Dr Scholl s Foot Comfort Shops Inc(Related Entity, United States(DE))
`|----Drovers ID Pty Ltd(Subsidiary, Australia(QL))
`|----DSD Holding A/S(Related Entity, Denmark)
`|----DSD Holding ApS(Subsidiary, Denmark)
`|----Elastec Srl(Subsidiary, Argentina)
`|----Essex Asia Ltd(Related Entity, Hong Kong)
`|----Essex Beteiligungs GmbH & Co KG(Related Entity, Germany)
`|----Essex Farmaceutica Portuguesa Lda(Related Entity, Portugal)
`|----Essex Farmaceutica SA(Related Entity, Colombia)
`|----Essex Holding GmbH(Related Entity, Germany)
`|----Essex Italia Srl(Related Entity, Italy)
`|----Essex Pharma Arzneimittel GmbH(Related Entity, Germany)
`|----Essex Pharma Distributions GmbH(Related Entity, Germany)
`|----Essex Pharma GmbH(Related Entity, Germany)
`|----Essex Pharma Vertriebs GmbH(Related Entity, Germany)
`|----Essex Pharmaceuticals Inc(Subsidiary, Philippines)
`|----Essex Verwaltungs GmbH(Related Entity, Germany)
`|----Essexfarm SA(Subsidiary, Ecuador)
`|----Farmaas BV(Related Entity, Netherlands)
`|----Farmaceutica Essex SA(Related Entity, Spain)
`|----Farmacox-Cia Farmaceutica Sociedade Uni Lda(Subsidiary, Portugal)
`|----Farmasix-Produtos Farmaceuticos Sociedade Uni Lda(Subsidiary, Portugal)
`|----Financiere MSD SAS(Subsidiary, France)
`|----Fontelabor-Produtos Farmaceuticos Sociedade Uni Lda(Subsidiary, Portugal)
`|----Fregenal Holdings SA(Related Entity, Panama)
`|----Frosst Laboratories Inc(Subsidiary, United States(DE))
`|----Frosst Portuguesa - Produtos Farmaceuticos Sociedade Uni Lda(Subsidiary, Portugal)
`|----Garden Insurance Co Ltd(Related Entity, Bermuda)
`|----Gestion MSDJ Canada Inc(Subsidiary, Canada(QC))
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`5
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 6
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Giralda Investments Ltd(Related Entity, Switzerland)
`|----Global Farm SA(Subsidiary, Argentina)
`|----Global Safety Surveillance LLC(Related Entity, United States)
`|----GlycoFi Inc(Subsidiary, United States(DE))
`|----Hangzhou MSD Pharmaceutical Co Ltd(Subsidiary, China(ZJ))
`|--------Hangzhou MSD Pharmaceutical Co Ltd/Shanghai(Branch Office, China)
`|----Harrisvaccines LLC(Related Entity, United States(IA))
`|----Hawk and Falcon LLC(Subsidiary, United States(DE))
`|----Healthcare Services and Solutions LLC(Subsidiary, United States(DE))
`|----Heptafarma - Cia Farmaceutica SUL Lda(Subsidiary, Portugal)
`|----HMR Weight Management Services Corp(Related Entity, United States(DE))
`|----Hoechst Roussel Vet de Bolivia Ltda(Related Entity, Bolivia)
`|----Horus BV(Related Entity, Netherlands)
`|----HSS Life-Science Holdings LLC(Related Entity, United States(DE))
`|----HSS Life-Science Solutions LLC(Related Entity, United States(DE))
`|----Hydrochemie GmbH(Subsidiary, Germany)
`|----Idenix GmbH(Subsidiary, Switzerland)
`|----Idenix Pharmaceuticals LLC(Related Entity, United States(DE))
`|--------Idenix Cayman Ltd(Subsidiary, Cayman Islands)
`|------------Idenix Sarl(Related Entity, France)
`|--------Idenix Massachusetts Inc(Subsidiary, United States(MA))
`|--------Idenix Securities Corp(Subsidiary, United States(MA))
`|----Identigen Canada Ltd(Subsidiary, Canada(AB))
`|----Identigen Czech SRO(Related Entity, Czech)
`|----Identigen Deutschland GmbH(Subsidiary, Germany)
`|----Identigen North America Inc(Subsidiary, United States(DE))
`|----Identigen Switzerland AG(Subsidiary, Switzerland)
`|----Ihsm BV(Subsidiary, Netherlands)
`|----IM Merial Holdings LLC(Related Entity, United States(DE))
`|----Imago Biosciences Inc(Subsidiary, United States(DE))
`|----Immune Design BV(Related Entity, Netherlands)
`|----Infomed SAS(Related Entity, France)
`|----InfoMedics International Inc(Related Entity, United States)
`|----Insight Acquisition Holdings Ltd(Related Entity, Ireland)
`|----Integrated Therapeutics Group Inc(Related Entity, United States(DE))
`|----International Indemnity Ltd(Subsidiary, Bermuda)
`|----Intervet AB(Subsidiary, Sweden)
`|----Intervet Agencies BV(Subsidiary, Netherlands)
`|--------Intervet Agencies BV/Kyiv(Branch Office, Ukraine)
`|----Intervet Animal Health Taiwan Ltd(Subsidiary, Taiwan)
`|----Intervet Argentina SA(Subsidiary, Argentina)
`|----Intervet Australia Pty Ltd(Subsidiary, Australia(VI))
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`6
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 7
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Intervet Belgium NV(Related Entity, Belgium)
`|----Intervet Bulgaria Eood(Related Entity, Bulgaria)
`|----Intervet Canada Corp(Subsidiary, Canada)
`|----Intervet Central America S de RL(Subsidiary, Panama)
`|----Intervet China BV(Subsidiary, Netherlands)
`|----Intervet CO Ltda(Related Entity, Colombia)
`|----Intervet Deutschland GmbH(Subsidiary, Germany)
`|----Intervet Ecuador SA(Subsidiary, Ecuador)
`|----Intervet Egypt for Animal Health SAE(Subsidiary, Egypt)
`|----Intervet Friesoythe GmbH(Related Entity, Germany)
`|----Intervet GesmbH(Subsidiary, Austria)
`|----Intervet Hellas AE(Subsidiary, Greece)
`|----Intervet Holding BV(Subsidiary, Netherlands)
`|--------MSD Animal Health UK Ltd(Related Entity, Britain)
`|----Intervet Holding Costa Rica SA(Related Entity, Costa Rica)
`|----Intervet Holding Iberia SL(Related Entity, Spain)
`|----Intervet Holdings France(Subsidiary, France)
`|----Intervet Hong Kong Ltd(Related Entity, Hong Kong)
`|----Intervet Hungaria Kft(Subsidiary, Hungary)
`|----Intervet Inc(Subsidiary, United States(DE))
`|----Intervet India Pvt Ltd(Subsidiary, India)
`|----Intervet Indonesia PT(Subsidiary, Indonesia)
`|----Intervet International BV(Subsidiary, Netherlands)
`|--------Farmaceutici Gellini Srl(Related Entity, Italy)
`|--------Invervet Inc USA(Related Entity, United States)
`|--------LIC Automation Ltd(Subsidiary, New Zealand)
`|----Intervet International GmbH(Subsidiary, Germany)
`|----Intervet International Sarl(Subsidiary, France)
`|----Intervet Ireland Ltd(Subsidiary, Ireland)
`|----Intervet Israel Ltd(Subsidiary, Israel)
`|----Intervet Italia Srl(Related Entity, Italy)
`|----Intervet KK(Related Entity, Japan)
`|----Intervet Korea Ltd(Related Entity, South Korea)
`|----Intervet LLC(Subsidiary, Russia)
`|----Intervet M Sdn Bhd(Subsidiary, Malaysia)
`|----Intervet Maroc SA(Subsidiary, Morocco)
`|----Intervet Mexico SA de CV(Subsidiary, Mexico)
`|----Intervet Middle East Ltd(Subsidiary, Cyprus)
`|----Intervet Nederland BV(Subsidiary, Netherlands)
`|----Intervet Norbio AS(Related Entity, Norway)
`|----Intervet Norbio Singapore Pte Ltd(Related Entity, Singapore)
`|----Intervet Norge AS(Subsidiary, Norway)
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`7
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 8
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Intervet Pharma R&D(Related Entity, France)
`|----Intervet Philippines Inc(Subsidiary, Philippines)
`|----Intervet Portugal-Saude Animal Lda(Related Entity, Portugal)
`|----Intervet Productions SA(Subsidiary, France)
`|----Intervet Productions Srl(Subsidiary, Italy)
`|----Intervet Pty Ltd(Subsidiary, South Africa)
`|----Intervet Romania SRL(Subsidiary, Romania)
`|----Intervet Rural Co Pty Ltd(Related Entity, Australia(VI))
`|----Intervet SA(Subsidiary, Peru)
`|----Intervet SAS/France(Subsidiary, France)
`|----Intervet Schering-Plough Animal Health Pty Ltd(Subsidiary, Australia(NS))
`|----Intervet South Africa Pty Ltd(Subsidiary, South Africa)
`|----Intervet Sp zoo(Subsidiary, Poland)
`|----Intervet SRO Czech Rep(Subsidiary, Czech)
`|----Intervet Thailand Ltd(Subsidiary, Thailand)
`|----Intervet UK Production Ltd(Subsidiary, Britain)
`|----Intervet Venezolana SA(Subsidiary, Venezuela)
`|----Intervet Veterinaria Chile Ltda(Subsidiary, Chile)
`|----Intervet Veteriner Ilaclari Pazarlama ve Ticaret Ltd Sirketi(Subsidiary, Tokelau)
`|----Interveterinaria SA de CV(Subsidiary, Mexico)
`|----IOmet Pharma Ltd(Subsidiary, Britain)
`|----Istituto Di Richerche Di Biologia Molecolare Srl(Related Entity, Italy)
`|----Istituto Gentili SpA/Inc(Subsidiary, Italy)
`|----Johnson & Johnson Consumer Pharma of Canada(Related Entity, Canada)
`|----Johnson & Johnson-MSD Consumer Pharmaceuticals Ltd(Subsidiary, Britain)
`|----KBI Inc(Subsidiary, United States(DE))
`|----KBI Sub Inc(Subsidiary, United States(DE))
`|----KBI-E Inc(Subsidiary, United States(DE))
`|----KBI-P Inc(Subsidiary, United States(DE))
`|----Key Pharma AG(Related Entity, Switzerland)
`|----Key Pharma SA(Related Entity, Spain)
`|----Key Pharmaceuticals Inc(Related Entity, United States(FL))
`|----Kiinteisto Oy Viistotie(Related Entity, Finland)
`|----Kirby Medical Products Cia Ltda(Related Entity, Chile)
`|----Kirby Pharmaceuticals SA(Related Entity, Spain)
`|----Koneksa Health Inc(Related Entity, United States(DE))
`|----Laboratoires White Du Canada Ltee(Related Entity, Canada(QC))
`|----Laboratoria Nobilis BV(Subsidiary, Netherlands)
`|----Laboratorio s SP White s CA(Related Entity, Venezuela)
`|----Laboratorios Abello SA(Subsidiary, Spain)
`|----Laboratorios Chibret SA(Related Entity, Spain)
`|----Laboratorios Essex CA(Related Entity, Venezuela)
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`8
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 9
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Laboratorios Essex SA(Related Entity, Argentina)
`|----Laboratorios Frosst SA(Related Entity, Spain)
`|----Laboratorios Medichip SL(Related Entity, Spain)
`|----Laboratorios Merial Peru SA(Subsidiary, Peru)
`|----Laboratorios Neurogard SA(Related Entity, Spain)
`|----Laboratorios Organon SA de CV(Related Entity, Mexico)
`|----Laboratorios Quimico-Farmaceuticos Chibret Sociedade Uni Lda(Subsidiary, Portugal)
`|----Lemifar SA(Subsidiary, Uruguay)
`|----Loftus Bryan Chemicals Ltd(Related Entity, Ireland)
`|----LOSPAR Partnership(Subsidiary, United States(DE))
`|----Maple Leaf Holdings GmbH(Related Entity, Switzerland)
`|----Maple Leaf Holdings Srl(Related Entity, Barbados)
`|----Marketing Communications of North Carolina LLC(Related Entity, United States(DE))
`|----Matsuken Yakuhin Kogyo KK(Subsidiary, Japan)
`|----Maya Tibbi Ltd Sirketi(Subsidiary, Turkey)
`|----Maya Tibbi Urunler Ticaret AS(Related Entity, Tokelau)
`|----MCM Vaccine BV(Subsidiary, Netherlands)
`|----MCM Vaccine Co(Related Entity, United States(PA))
`|----MED Help International Inc(Related Entity, United States(DE))
`|----Med-Nim Pty Ltd(Related Entity, South Africa)
`|----MedAdvisor Inc(Related Entity, United States(DE))
`|----Medco de Mexico Managed Care S de RL de CV(Subsidiary, Mexico)
`|----Medco Holdings S de RL de CV(Subsidiary, Mexico)
`|----Medco Servicios de Mexico S de RL de CV(Subsidiary, Mexico)
`|----Merck & Co Inc Master Retirement Trust(Subsidiary, United States(NJ))
`|----Merck & Co Inc/Bermuda(Branch Office, Bermuda)
`|----Merck and Co Inc Union Veba Trust(Related Entity, United States)
`|----Merck and Co Inc/DE(Subsidiary, United States(DE))
`|----Merck Animal Health(Subsidiary, United States)
`|--------Identigen Ltd(Subsidiary, Ireland)
`|--------Pixobot Inc(Related Entity, United States(DE))
`|--------Vaki A/S(Subsidiary, Iceland)
`|--------Vaki aquaculture system Ltd(Subsidiary, Iceland)
`|--------Vallee SA(Subsidiary, France)
`|--------Vallee SA/Brazil(Related Entity, Brazil)
`|----Merck Borinquen Holdings Inc(Subsidiary, United States(DE))
`|----Merck Canada Inc(Subsidiary, Canada(QC))
`|----Merck Capital Resources Inc(Subsidiary, United States(DE))
`|----Merck Capital Ventures LLC(Subsidiary, United States(DE))
`|----Merck Cardiovascular Health Co(Related Entity, United States(NV))
`|----Merck Co Foundation(Affiliate, United States)
`|----Merck Finance Co Inc(Subsidiary, United States(DE))
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`9
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 10
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Merck Foreign Sales Corp Ltd(Subsidiary, Bermuda)
`|----Merck Frosst Canada & Co(Subsidiary, Canada)
`|----Merck Frosst Canada Ltd(Related Entity, Canada(QC))
`|----Merck Frosst Co(Subsidiary, Canada)
`|----Merck Frosst Finco LP(Related Entity, Canada)
`|----Merck Frosst Schering Pharma GP(Related Entity, Canada)
`|----Merck Global Health Innovation Fund LLC(Subsidiary, United States(DE))
`|--------Octave Bioscience Inc(Subsidiary, United States(DE))
`|----Merck Global Health Innovation Pvt Equity LLC(Subsidiary, United States(DE))
`|----Merck Global Research LLC(Related Entity, United States(DE))
`|----Merck HDAC Research LLC(Subsidiary, United States(DE))
`|----Merck Holdings II Corp(Subsidiary, United States(DE))
`|----Merck Holdings III Corp(Related Entity, United States(DE))
`|----Merck Holdings Inc(Related Entity, United States(DE))
`|----Merck Holdings IV Corp(Subsidiary, United States(DE))
`|----Merck Holdings LLC(Subsidiary, United States(DE))
`|----Merck Institute for Vaccinology(Subsidiary, United States(DE))
`|----Merck International Holdings Corp(Subsidiary, United States(DE))
`|----Merck Investment Co Inc(Subsidiary, United States(DE))
`|----Merck LMC Cash Management Bermuda Ltd(Subsidiary, Bermuda)
`|----Merck Oncology Holdings Inc(Subsidiary, United States(DE))
`|----Merck Registry Holdings Inc(Subsidiary, United States(NJ))
`|----Merck Research Investments LLC(Subsidiary, United States(DE))
`|----Merck Research Laboratories Massachusetts LLC(Subsidiary, United States(DE))
`|----Merck Resource Management Inc(Subsidiary, United States(DE))
`|----Merck Sharp & Dohme Algerie Sarl(Related Entity, Algeria)
`|----Merck Sharp & Dohme Animal Health SL(Subsidiary, Spain)
`|----Merck Sharp & Dohme Argentina LLC(Subsidiary, Argentina(DE))
`|----Merck Sharp & Dohme Asia Ltd(Subsidiary, Hong Kong)
`|----Merck Sharp & Dohme Asia Pacific Services Pte Ltd(Subsidiary, Singapore)
`|----Merck Sharp & Dohme Australia Pty Ltd(Subsidiary, Australia(NS))
`|----Merck Sharp & Dohme BH doo(Subsidiary, Bosnia-herze.)
`|----Merck Sharp & Dohme Biologics Ireland Ltd(Related Entity, Ireland)
`|----Merck Sharp & Dohme Bulgaria EOOD(Subsidiary, Bulgaria)
`|----Merck Sharp & Dohme BV(Subsidiary, Netherlands)
`|--------Laboratoires Merck Sharp & Dohme-Chibret SAS(Subsidiary, France)
`|--------MSD Farmasyutikals OOO(Subsidiary, Russia)
`|----Merck Sharp & Dohme Chibret AG(Related Entity, Switzerland)
`|----Merck Sharp & Dohme Chile Ltda(Subsidiary, Chile)
`|----Merck Sharp & Dohme China Ltd(Subsidiary, China)
`|----Merck Sharp & Dohme Colombia SAS(Subsidiary, Colombia)
`|----Merck Sharp & Dohme Comercializadora S de RL de CV(Subsidiary, Mexico)
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`10
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 11
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Merck Sharp & Dohme Corp(Related Entity, United States(NJ))
`|--------Immune Design Corp(Subsidiary, United States(DE))
`|----Merck Sharp & Dohme Cyprus Ltd(Subsidiary, Cyprus)
`|----Merck Sharp & Dohme de Espana SAU(Subsidiary, Spain)
`|----Merck Sharp & Dohme de Mexico SA de CV(Related Entity, Mexico)
`|----Merck Sharp & Dohme de Puerto Rico Inc(Related Entity, United States(DE))
`|----Merck Sharp & Dohme de Venezuela Srl(Related Entity, Venezuela)
`|----Merck Sharp & Dohme doo(Subsidiary, Croatia)
`|----Merck Sharp & Dohme doo Belgrade(Subsidiary, Serbia)
`|----Merck Sharp & Dohme Enterprises BV(Subsidiary, Netherlands)
`|----Merck Sharp & Dohme Europe Inc(Subsidiary, United States(DE))
`|--------Merck Sharp & Dohme Europe Inc/Brussels(Branch Office, Belgium(DE))
`|----Merck Sharp & Dohme Farmaceutica Ltda(Subsidiary, Brazil)
`|----Merck Sharp & Dohme Finance Europe Ltd(Subsidiary, Britain)
`|----Merck Sharp & Dohme GesmbH(Subsidiary, Austria)
`|----Merck Sharp & Dohme GmbH(Related Entity, Austria)
`|----Merck Sharp & Dohme Holdings BV(Related Entity, Netherlands)
`|----Merck Sharp & Dohme Holdings Corp(Subsidiary, United States(DE))
`|----Merck Sharp & Dohme Holdings de Mexico SA de CV(Subsidiary, Mexico)
`|----Merck Sharp & Dohme Holdings Pty Ltd(Subsidiary, Australia(NS))
`|----Merck Sharp & Dohme IA Corp(Related Entity, Taiwan(DE))
`|----Merck Sharp & Dohme IA Corp/Malaysia(Subsidiary, Malaysia)
`|----Merck Sharp & Dohme IA LLC(Subsidiary, United States(DE))
`|--------Merck Sharp & Dohme IA LLC/Carolina(Branch Office, Puerto Rico)
`|--------Merck Sharp & Dohme IA LLC/Quito(Branch Office, Ecuador)
`|--------Merck Sharp & Dohme IA LLC/Taiwan(Branch Office, Taiwan)
`|----Merck Sharp & Dohme IDEA GmbH(Subsidiary, Switzerland)
`|--------Merck Sharp & Dohme IDEA AG/Amman(Branch Office, Jordan)
`|--------Merck Sharp & Dohme Idea Inc(Subsidiary, Slovakia)
`|------------Merck Sharp & Dohme Idea Inc/Algeria(Branch Office, Algeria)
`|------------Merck Sharp & Dohme IDEA Inc/Bratislava(Branch Office, Slovakia)
`|------------Merck Sharp & Dohme Idea Inc/Russia(Branch Office, Russia)
`|------------Merck Sharp & Dohme Idea Inc/Ukraine(Branch Office, Ukraine)
`|----Merck Sharp & Dohme Indonesia PT(Subsidiary, Indonesia)
`|----Merck Sharp & Dohme Industria Quimica e Veterinaria Ltda(Related Entity, Brazil)
`|----Merck Sharp & Dohme Inovativna Zdravila doo(Subsidiary, Slovenia)
`|----Merck Sharp & Dohme International Ltd(Subsidiary, Bermuda)
`|----Merck Sharp & Dohme International Services BV(Subsidiary, Netherlands)
`|----Merck Sharp & Dohme Investments BV(Related Entity, Netherlands)
`|----Merck Sharp & Dohme Ireland Human Health Ltd(Subsidiary, Ireland)
`|----Merck Sharp & Dohme Ireland Ltd(Related Entity, Ireland)
`|----Merck Sharp & Dohme Island ehf(Related Entity, Iceland)
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`11
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 12
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Merck Sharp & Dohme Israel-1996 Co Ltd(Subsidiary, Israel)
`|----Merck Sharp & Dohme Israel-1999 Co Ltd(Related Entity, Israel)
`|----Merck Sharp & Dohme Italia SpA(Related Entity, Italy)
`|----Merck Sharp & Dohme Italia Srl(Related Entity, Italy)
`|----Merck Sharp & Dohme Japan Co Ltd(Related Entity, Japan)
`|----Merck Sharp & Dohme Lebanon SAL(Subsidiary, Lebanon)
`|----Merck Sharp & Dohme LLC(Subsidiary, United States(NJ))
`|----Merck Sharp & Dohme Ltda(Subsidiary, Portugal)
`|----Merck Sharp & Dohme Ltda/Bolivia(Subsidiary, Bolivia)
`|----Merck Sharp & Dohme Luxembourg Holdings Sarl(Subsidiary, Luxembourg)
`|----Merck Sharp & Dohme Malaysia Sdn Bhd(Subsidiary, Malaysia)
`|----Merck Sharp & Dohme Manufacturing Holdings(Related Entity, Bermuda)
`|----Merck Sharp & Dohme Manufacturing ULC(Subsidiary, Ireland)
`|----Merck Sharp & Dohme Middle East Ltd(Subsidiary, Cyprus)
`|----Merck Sharp & Dohme New Zealand Ltd(Subsidiary, New Zealand)
`|----Merck Sharp & Dohme of Pakistan Ltd(Subsidiary, Pakistan)
`|----Merck Sharp & Dohme OU(Subsidiary, Estonia)
`|----Merck Sharp & Dohme Panama SA(Subsidiary, Panama)
`|----Merck Sharp & Dohme Peru Srl(Subsidiary, Peru)
`|----Merck Sharp & Dohme Pharmaceutical Industrial & Commercial SA(Subsidiary, Greece)
`|----Merck Sharp & Dohme Pharmaceuticals(Related Entity, Bermuda)
`|----Merck Sharp & Dohme Pharmaceuticals LLC(Related Entity, Russia)
`|----Merck Sharp & Dohme Pharmaceuticals Srl(Related Entity, Barbados)
`|----Merck Sharp & Dohme Philippines Inc(Related Entity, Philippines)
`|----Merck Sharp & Dohme Puerto Rico Ltd(Related Entity, Bermuda)
`|----Merck Sharp & Dohme Quimica de Puerto Rico Inc(Related Entity, Puerto Rico(DE))
`|----Merck Sharp & Dohme Research GmbH(Subsidiary, Switzerland)
`|----Merck Sharp & Dohme Research Ltd(Related Entity, Bermuda)
`|----Merck Sharp & Dohme Romania Srl(Subsidiary, Romania)
`|----Merck Sharp & Dohme S de RL de CV(Subsidiary, Mexico)
`|----Merck Sharp & Dohme SA(Subsidiary, Morocco)
`|----Merck Sharp & Dohme Salud Animal Columbia SAS(Subsidiary, Colombia)
`|----Merck Sharp & Dohme Saude Animal Ltda(Subsidiary, Brazil)
`|----Merck Sharp & Dohme SIA(Subsidiary, Latvia)
`|----Merck Sharp & Dohme Singapore Ltd(Related Entity, Singapore)
`|----Merck Sharp & Dohme Singapore Manufacturing Ltd(Subsidiary, Bermuda)
`|----Merck Sharp & Dohme Sro/Czech Republic(Subsidiary, Czech)
`|----Merck Sharp & Dohme sro/Slovakia(Subsidiary, Slovakia)
`|----Merck Sharp & Dohme Sweden AB(Subsidiary, Sweden)
`|----Merck Sharp & Dohme Switzerland GmbH(Subsidiary, Switzerland)
`|----Merck Sharp & Dohme Tunisie Sarl(Subsidiary, Tunisia)
`|----Merck Sharp & Dohme UAB(Subsidiary, Lithuania)
`
`www.bloomberglaw.com © 2023 The Bureau of National Affairs, Inc. All Rights
`Reserved.
`
`12
`
`Generated 05/23/23
`
`Acerta Exhibit 2010
`Sandoz Inc. v. Acerta Pharma B.V.
`IPR2023-00478
`Page 13
`
`

`

`This document is being provided for the exclusive use of Matt Foley at WILLIAMS&CONNOLLY LLP
`
`|----Merck Sharp & Dohme UK Ltd(Subsidiary, Britain)
`|----Merck Sharp Dohme Ilaclari Ltd Sirketi(Subsidiary, Turkey)
`|----Merck Technology US Co Inc(Related Entity, United States(NV))
`|----Merck Teknika LLC(Subsidiary, United States(DE))
`|----Merck Ventures Inc(Subsidiary, United States(DE))
`|----Merck-Banyu Co Ltd(Subsidiary, Japan)
`|----Merck-Medco Managed Care Inc(Related Entity, United States(DE))
`|--------Medical Marketing Group Inc/NJ(Related Entity, United States(DE))
`|--------Systemed Inc(Related Entity, United States(DE))
`|------------Newport Pharmaceuticals de Costa Rica(Subsidiary, Costa Rica)
`|----Merko Acquisition SA(Subsidiary, Belgium)
`|----Merko BV(Related Entity, Netherlands)
`|----Merko Dalton BV(Subsidiary, Netherlands)
`|----Merko Dalton Continental BV(Related Entity, Netherlands)
`|----Merko NV(Subsidiary, Belgium)
`|----Mikasu Corp(Subsidiary, Japan)
`|----ML Holdings Canada Inc(Subsidiary, Canada)
`|----MMUSA Acquisition II Corp(Related Entity, United States(DE))
`|----